Registration and prospectus / Cyclacel Pharmaceuticals, Inc. | Tables in SEC filings

CYCC Cyclacel Pharmaceuticals, Inc.

IPO registration

The following table sets forth our cash and cash equivalents, debt obligations, and capitalization as of June 30, 2024 (i) on an actual basis; and (ii) on a pro forma as adjusted basis to give effect to the issuance and sale of shares of our common stock and Common Stock Warrants based on an assumed public offering price, based on the last reported sale price on , 2024 of $ per share, for total net proceeds of approximately $ (assuming no sale of pre- funded warrants).

	June 30, 2024		As Adjusted
Cash and cash equivalents	$	6,000		$
Total liabilities		7,191

Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized at June 30, 2024;		—
6% Convertible Exchangeable preferred stock; 335,273 shares issued and outstanding at June 30, 2024. Aggregate preference in liquidation of $4,006,512 as of June 30, 2024		—
Series A convertible preferred stock, $0.001 par value; 264 shares issued and outstanding at June 30, 2024		—
Series B convertible preferred stock, $0.001 par value; 0 shares issued and outstanding at June 30, 2024		—
Common stock, $0.001 par value; 100,000,000 shares authorized at June 30, 2024; 1,805,204 shares issued and outstanding at June 30, 2024		2
Additional paid-in capital		436,397
Accumulated other comprehensive loss		(915)
Accumulated deficit		(431,485)
Total stockholders’ equity		999
Total liabilities and stockholders’ equity	$	8,190		$

Assumed public offering price per share (attributing no value to the warrants)	$
Net tangible book value per share as of June 30, 2024	$	0.55
Decrease in pro forma as adjusted net tangible book value per share after this offering	$
Pro forma as adjusted net tangible book value per share after giving effect of this offering	$
Dilution in pro forma as adjusted net tangible book value per share to new investors	$

Name of Selling Stockholder	Number of shares of Common Stock Owned Prior to Offering			Maximum Number of shares of Common Stock to be Sold Pursuant to this Prospectus			Number of shares of Common Stock Owned After Offering
Armistice Capital, LLC (1)		4,968,945	(2)		14,906,835	(3)		-
Michael Vasinkevich (4)		-			191,180	(5)		-
Noam Rubinstein (4)		-			93,913	(6)		-
Craig Schwabe (4)		-			10,062	(7)		-
Charles Worthman (4)		-			2,982	(8)		-
TOTAL					15,204,972

		% of		% of		% of		% of
	100%	Total	75%	Total	50%	Total	25%	Total
Gross Proceeds from Offering	$10,000,000	100.00%	$7,500,000	100.00%	$5,000,000	100.00%	$2,500,000	100.00%
Offering Expenses
Placement Agent Commissions	$700,000	7.00%	$525,000	7.00%	$350,000	7.00%	$175,000	7.00%
Placement Agent Expenses	$100,000	1.00%	$100,000	1.33%	$100,000	2.00%	$100,000	4.00%
Other Offering Expenses	$329,428	3.29%	$329,428	4.39%	$329,428	6.59%	$329,428	13.18%
Total	$1,129,428	11.29%	$954,428	12.73%	$779,428	15.59%	$604,428	24.18%
Net Proceeds	$8,870,572	88.71%	$6,545,572	87.27%	$4,220,572	84.41%	$1,895,572	75.82%

Audit	$	7,500
Compensation and Organization Development	$	5,000
Nominating and Corporate Governance	$	4,000
Science and Technology	$	4,000

Table search / Registration and prospectus / Cyclacel Pharmaceuticals, Inc.

134 results

Top filers

Top filing types

Recent filing years